Anti-Epcr/PROCR antibody

Anti-Epcr/PROCR antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit monoclonal to Epcr/PROCR

IHC-P

Human Epcr / PROCR
No cross-reactivity in ELISA with Mouse PROCR

CCCA antibody; EPCR antibody; CCD41 antibody; Ccca antibody; Epcr antibody; Ccd41 antibody; AI325044 antibody; AI325044 antibody; bA42O4.2 antibody; CCCA antibody; Ccca antibody; Ccd41 antibody; CCD41 antibody; CD201 antibody; EPCR antibody; Epcr antibody; MGC23024 antibody; RP23-388H13.2 antibody

Rabbit IgG

This antibody was obtained from a rabbit immunized with purified, recombinant Human Epcr / PROCR (rh Epcr / PROCR; Q9UNN8; Met1-Thr209).

Monoclonal

0.2 μm filtered solution in PBS

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Endothelial protein C receptor (EPCR), also known as activated protein C receptor (APC receptor) or PROCR, is a receptor for Protein C. Protein C plays an important role in many metabolism processes in humans and other animals after activated by binding to Endothelial protein C receptor (EPCR). Because of the EPCR is found primarily on endothelial cells (cells on the inside of blood vessels), activated protein C is found maily near endothelial cells. Protein C is pleiotropic, with two main functions: anticoagulation and cytoprotection. Which function will be performed depend on whether or not protein C remains bind to EPCR after activated. The anticoagulation occurs when it does not. In this case, protein C functions as an anticoagulant by irreversibly proteolytically inactivating Factor Va and Factor VIIIa, turning them into Factor Vi and Factor VIIIi respectively. When still bound to EPCR, activated protein C performs its cytoprotective effects, acting on the effector substrate PAR-1, protease-activated receptor-1. To a degree, APC's anticoagulant properties are independent of its cytoprotective ones, in that expression of one pathway is not affected by the existence of the other. 

• Nicolaes GA, et al. (2003). Congenital and acquired activated protein C resistance. Semin Vasc Med. 3 (1): 33-46.
• Esmon CT. ( 2003). The protein C pathway. Chest 124 (3): 26-32.
• Mosnier LO, et al. (2007)The cytoprotective protein C pathway. Blood. 109: 3161-72.